Ekso Bionics (NASDAQ:EKSO) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report released on Monday. The brokerage issued a hold rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Ekso Bionics in a research report on Tuesday, January 14th.

Ekso Bionics Stock Down 8.1 %

Shares of EKSO stock opened at $0.48 on Monday. The firm’s fifty day moving average price is $0.61 and its two-hundred day moving average price is $0.83. The company has a current ratio of 2.81, a quick ratio of 2.14 and a debt-to-equity ratio of 0.28. Ekso Bionics has a 1 year low of $0.47 and a 1 year high of $2.16. The firm has a market capitalization of $10.61 million, a P/E ratio of -0.74 and a beta of 1.46.

Ekso Bionics (NASDAQ:EKSO) last released its earnings results on Monday, March 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.07). Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. The company had revenue of $5.09 million during the quarter, compared to analyst estimates of $5.05 million. On average, equities analysts predict that Ekso Bionics will post -0.48 EPS for the current fiscal year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.